Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature

Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature

Background: Despite multidisciplinary treatment approaches, the prognosis for patients with high-grade glioma (HGG) is poor, with a median overall survival (OS) of 14.6 months for glioblastoma multiforme (GB). As high levels of vascular endothelial growth factor A (VEGF) are found in HGG, targeted a...

Full description

Bibliographic Details
Main Authors: Jennifer Jeck, Rebecca Kassubek, Jan Coburger, Simone Edenhofer, Stefan S. Schönsteiner, Albert C. Ludolph, Bernd Schmitz, Jens Engelke, Regine Mayer-Steinacker, Jan Lewerenz, Lars Bullinger
Format: Article
Language:English
Published: SAGE Publishing 2018-01-01
Series:Therapeutic Advances in Neurological Disorders
Online Access:https://doi.org/10.1177/1756285617753597

Internet

https://doi.org/10.1177/1756285617753597

Similar Items